Evidence map›Paper›PMID 35008258›Full record

ArticleCancers2021

Validating an Instrument for Direct Patient Reporting of Distress and Chemotherapy-Related Toxicity among South African Cancer Patients.

Charmaine L Blanchard, Keletso Mmoledi, Michael H Antoni, Georgia Demetriou, Maureen Joffe, Gilberto Lopes, Paul Ruff, Daniel S O'Neil

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact, top 78% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Charmaine L BlanchardCentre for Palliative Care, Department of Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2193, South Africa.ORCID 0000-0002-9302-1454
Keletso MmolediNon-Communicable Disease Research Division, Wits Health Consortium (PTY) Ltd., Johannesburg 2193, South Africa.
Michael H AntoniSylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL 33136, USA.
Georgia DemetriouDivision of Medical Oncology, Department of Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2193, South Africa.
Maureen JoffeNon-Communicable Disease Research Division, Wits Health Consortium (PTY) Ltd., Johannesburg 2193, South Africa.
Gilberto LopesSylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL 33136, USA.
Paul RuffNon-Communicable Disease Research Division, Wits Health Consortium (PTY) Ltd., Johannesburg 2193, South Africa.
Daniel S O'NeilSylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL 33136, USA.
University of the Witwatersrand · ZAUniversity of Miami Health System · USAfrica Health Research Institute · ZAUniversity of Miami · US

Funding

UM Calabresi Clinical Oncology Research Career Development AwardK12CA226330 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Alan Pollack · 2018 to 2026
$5.1M
Novel predictors of survival among breast cancer patients with/without HIV in South AfricaR01CA250012 · NCI · WITS HEALTH CONSORTIUM (PTY), LTD · PI CUBASCH, HERBERT, EL-SADR, WAFAA M. · 2020 to 2024
$2.0M
HIV's Effects on Breast Cancer Treatment and Outcomes in South AfricaR01CA192627 · NCI · WITS HEALTH CONSORTIUM (PTY), LTD · PI JACOBSON, JUDITH S, JOFFE, MAUREEN · 2015 to 2019
$1.7M
NCI NIH HHS K12 CA226330NCI NIH HHS K12CA226330NCI NIH HHS R01 CA192627NCI NIH HHS R01 CA250012Sylvester Comprehensive Cancer Center Global Oncology Innovation GrantUniversity of the Witwatersrand the Cassandra Miller-Butterworth Wits Clinician Scientist PhD Fellowship
6 · The paper itself

Abstract

Patient-reported outcome measures (PROM) for monitoring treatment toxicity improve quality of life (QoL) and clinical outcomes. However, no such PROMs exist for sub-Saharan African cancer patients. We aimed to validate the Patient Reported Symptoms-South Africa (PRS-SA) survey, a novel PROM for measuring distress and chemotherapy-related symptoms in South African cancer patients. We enrolled patients at the oncology clinic at Charlotte Maxeke Hospital, Johannesburg. At three separate visits, participants simultaneously completed the PRS-SA survey and several previously validated questionnaires. We constructed a receiver operator characteristics curve for distress levels predicting a Hospital Anxiety and Depression Scale (HADS) score ≥15. We evaluated construct validity for symptom items by comparing severity to the EORTC Core Quality of Life Questionnaire (QLQ-C30) summary score (Pearson correlation tests) and ECOG performance status (Mann-Whitney U tests). We assessed symptom item responsiveness by comparing change in severity to change in QLQ-C30 summary score and comparing standardized mean scores with negative, no, or positive change on the Global Impression of Change (GIC) questionnaire (Jockheere-Terpstra trend test). Overall, 196 participants with solid tumors completed instruments. A distress score of 4 had 82% sensitivity and 55% specificity for clinical depression/anxiety. All symptom items showed construct validity by association with either QLQ-C30 score or performance status (highest

Indexed as

chemotherapy toxicitydistresspatient reported outcomesquality of lifeSouth Africa

Identifiers

PMID35008258
PMCPMC8750185
OpenAlexW4200152972

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.